Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955640 · ClinicalTrials.gov registry record · Phase 1
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
A Phase 1 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03955640 is a Phase 1 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 3 participants.
The verdict
NCT03955640, a Phase 1 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia treatment may kill or damage tumor cells by heating them to several degrees above normal body temperature. Giving olaparib and hyperthermia treatment may work better in treating patients with breast cancer that has come back in the chest well compared to standard of care.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Olaparib
- OTHER Questionnaire Administration
- PROCEDURE Hyperthermia Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2021-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955640
The ClinicalTrials.gov registry entry for NCT03955640 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03955640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03955640 about?
NCT03955640 is a clinical study titled "Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences". This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hyperthermia treatment ...
What is the current status of trial NCT03955640?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-05-20. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT03955640?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Olaparib (DRUG), Questionnaire Administration (OTHER), Hyperthermia Treatment (PROCEDURE).
Who is sponsoring clinical trial NCT03955640?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.